{"id":"W2905757675","doi":"10.1182/blood-2018-99-118551","title":"Polatuzumab Vedotin (Pola) Plus Bendamustine (B) with Rituximab (R) or Obinutuzumab (G) in Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL): Updated Results of a Phase (Ph) Ib/II Study","year":2018,"lang":"en","type":"article","venue":"Blood","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":23,"is_retracted":false,"has_abstract":true,"ca_institutions":"Roche (Canada); McGill University; BC Cancer Agency","funders":"","keywords":"Medicine; Diffuse large B-cell lymphoma; Rituximab; Internal medicine; Bendamustine; Gastroenterology; Oncology; Nuclear medicine; Lymphoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001879255,0.0004847372,0.001101144,0.0002715766,0.0001463943,0.001119986,0.0005352114,0.0003565921,0.001643688],"category_scores_gemma":[0.0009719793,0.0003074243,0.001300954,0.0004422214,0.0002807201,0.000600349,0.0002808949,0.001348081,0.0003727784],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006323448,"about_ca_system_score_gemma":0.0005568502,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004972872,"about_ca_topic_score_gemma":0.001371225,"domain_scores_codex":[0.9994974,0.0002535783,0.0000506984,0.0000851165,0.00005759287,0.00005555946],"domain_scores_gemma":[0.999248,0.0001841173,0.0002622481,0.00007303851,0.00006140672,0.0001710391],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.5383292,0.00875539,0.04265814,0.003413285,0.01017305,0.0002346947,0.0002714065,0.002580825,0.02925511,0.0004578966,0.005490346,0.3583807],"study_design_scores_gemma":[0.4822743,0.2963091,0.1520743,0.00109022,0.02617637,0.00136015,0.0003273069,0.002637526,0.01023017,0.001143573,0.02627105,0.0001059146],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9679078,0.02570669,0.000651477,0.000609434,0.0001492719,0.0005746009,0.001888222,0.00005215413,0.002460306],"genre_scores_gemma":[0.9867134,0.007402542,0.0008177242,0.0008826542,0.0001623204,0.0003645326,0.002722161,0.00001829345,0.0009163148],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.001879255,"threshold_uncertainty_score":0.009938598,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01508975381121335,"score_gpt":0.2740723254785748,"score_spread":0.2589825716673614,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}